Akero Therapeutics (AKRO)
(Delayed Data from NSDQ)
$48.37 USD
-0.48 (-0.98%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $48.17 -0.20 (-0.41%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AKRO 48.37 -0.48(-0.98%)
Will AKRO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AKRO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AKRO
Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect
Amarin Gears Up to Report Q2 Earnings: Here's What to Expect
AKRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth?
Other News for AKRO
Altimmune: Potential Tough Road Ahead Amid Fierce Competition (Rating Downgrade)
Insider Sell: Andrew Cheng Sells 30,000 Shares of Akero Therapeutics Inc (AKRO)
Akero Therapeutics’ Efruxifermin Study: A Potential Game-Changer for NASH/MASH Treatment
Logos Global Management LP Acquires 4,800,000 Shares in Arvinas Inc
Akero Therapeutics (AKRO) Emerges as Attractive Acquisition Target | AKRO Stock News